DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction on Friday, September 14th. The shares were sold at an average price of $145.17, for a total transaction of $725,850.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrew K. Balo also recently made the following trade(s):

  • On Tuesday, August 14th, Andrew K. Balo sold 5,000 shares of DexCom stock. The shares were sold at an average price of $124.25, for a total transaction of $621,250.00.
  • On Monday, July 16th, Andrew K. Balo sold 5,000 shares of DexCom stock. The shares were sold at an average price of $99.56, for a total transaction of $497,800.00.

DexCom stock traded up $1.38 during midday trading on Tuesday, hitting $139.31. 1,097,200 shares of the stock were exchanged, compared to its average volume of 1,132,213. DexCom, Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $148.56. The stock has a market cap of $12.64 billion, a P/E ratio of -240.94 and a beta of 0.44. The company has a current ratio of 4.89, a quick ratio of 4.62 and a debt-to-equity ratio of 0.69.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, August 1st. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The firm had revenue of $242.50 million during the quarter, compared to analysts’ expectations of $205.81 million. During the same period last year, the business earned ($0.16) earnings per share. DexCom’s revenue was up 42.1% compared to the same quarter last year. analysts forecast that DexCom, Inc. will post -0.47 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Morgan Stanley increased its position in DexCom by 16.3% during the second quarter. Morgan Stanley now owns 5,028,874 shares of the medical device company’s stock worth $477,644,000 after purchasing an additional 705,072 shares during the last quarter. BlackRock Inc. increased its position in DexCom by 5.9% during the second quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock worth $390,978,000 after purchasing an additional 228,933 shares during the last quarter. JPMorgan Chase & Co. increased its position in DexCom by 8.9% during the first quarter. JPMorgan Chase & Co. now owns 2,588,232 shares of the medical device company’s stock worth $191,943,000 after purchasing an additional 211,250 shares during the last quarter. Point72 Asset Management L.P. increased its position in DexCom by 25.1% during the second quarter. Point72 Asset Management L.P. now owns 1,225,344 shares of the medical device company’s stock worth $116,383,000 after purchasing an additional 246,169 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in DexCom by 0.3% during the first quarter. Franklin Resources Inc. now owns 1,169,066 shares of the medical device company’s stock worth $86,698,000 after purchasing an additional 3,183 shares during the last quarter.

Several research firms have recently weighed in on DXCM. BMO Capital Markets raised their price target on shares of DexCom to $112.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 10th. Piper Jaffray Companies raised their price target on shares of DexCom to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 12th. Bank of America raised their price target on shares of DexCom from $106.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Berenberg Bank raised shares of DexCom from a “hold” rating to a “buy” rating and set a $140.00 price target on the stock in a research note on Monday, August 6th. Finally, Jefferies Financial Group raised their price target on shares of DexCom from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $111.64.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: How to Invest in Growth Stocks

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.